18.18
1.34 (7.96%)
| Previous Close | 16.84 |
| Volume | 541,633 |
| Price / Earnings (Forward) | 454.55 |
| Price / Sales | 30.52 |
| Price / Book | 3.80 |
| 52 Weeks Range |
| Operating Margin (TTM) | -633.21% |
| Diluted EPS (TTM) | -1.24 |
| Quarterly Revenue Growth (YOY) | -6.80% |
| Total Debt/Equity (MRQ) | 27.34% |
| Current Ratio (MRQ) | 0.960 |
| Operating Cash Flow (TTM) | -42.54 M |
| Levered Free Cash Flow (TTM) | -13.46 M |
| Return on Assets (TTM) | -4.85% |
| Return on Equity (TTM) | -21.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Mesoblast Limited | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 0.06% |
| % Held by Institutions | 3.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Prosperity Wealth Management, Inc. | 31 Dec 2025 | 50,900 |
| Lazari Capital Management, Inc. | 30 Jun 2026 | 47,421 |
| Rialto Wealth Management, Llc | 30 Jun 2026 | 46,500 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |